# Phrontline Biopharma Highlights Encouraging Preliminary Safety and Antitumor Activity of TJ101 Presented at ESMO 2026 and Announces Phase Ib Initiation

- Source: PR Newswire M&A
- Published: 2026-10-30T01:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/phrontline-biopharma-highlights-encouraging-preliminary-safety-and-antitumor-activity-of-tj101-presented-at-esmo-2026-and-announces-phase-ib-initiation-302924408.html
- Canonical: https://groundlevelnews.com/story/phrontline-biopharma-highlights-encouraging-preliminary-safety-and-ant-0855ed/

Preliminary responses observed in 6 of 8 evaluable urothelial carcinoma patients (75%), including patients previously treated with enfortumab vedotin and pembrolizumab Early antitumor activity also observed in squamous NSCLC, SCLC and prostate cancer SHANGHAI and HANGZHOU, China, Oct. 29,...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._